Innate Pharma shares surged 25%+ after it announced a strategic partnership with Swedish Orphan Biovitrum (Sobi) to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study of lacutamab. The agreement is a key clinical de-risking milestone for the company’s lead investigational asset and supported a sharp positive repricing of the stock.
Innate Pharma shares surged 25%+ after it announced a strategic partnership with Swedish Orphan Biovitrum (Sobi) to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study of lacutamab. The agreement is a key clinical de-risking milestone for the company’s lead investigational asset and supported a sharp positive repricing of the stock.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.60
Ticker Sentiment
